Dr Lal PathLabs to acquire 70 percent stake in Amins Pathology Referral Laboratory
New Delhi: Diagnostic chain Dr Lal PathLabs said the board of its arm PathLabs Unifiers has approved acquisition of 70 per cent stake in Amins Pathology Referral Laboratory to strengthen its presence in Gujarat. "We are pleased to announce the acquisition of a proprietorship concern, 'Amins Pathology Referral Laboratory' by our subsidiary PathLabs Unifiers Pvt Ltd which operates diagnostics networks in Vadodara, Gujarat," Dr Lal PathLabs CEO Om Manchanda said.
Also read:- Laurus Labs to acquire subsidiary of ASPEN Pharmacare
The acquisition will further strengthen the company's network in Gujarat and adjoining areas, he added. Shares of Dr Lal PathLabs on Tuesday closed at Rs 1,367.20 per scrip on the BSE, down 1.52 per cent from its previous close.
Also read:- Roche gets USFDA clearance for cobas pro solutions for diagnostics labs
Also read:- Laurus Labs to acquire subsidiary of ASPEN Pharmacare
The acquisition will further strengthen the company's network in Gujarat and adjoining areas, he added. Shares of Dr Lal PathLabs on Tuesday closed at Rs 1,367.20 per scrip on the BSE, down 1.52 per cent from its previous close.
Also read:- Roche gets USFDA clearance for cobas pro solutions for diagnostics labs
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd